Quick Math According to recent clinical data, up to 40% of weight lost on GLP-1s is lean mass, not fat
The SEMALEAN study (2025): "Semaglutide treatment resulted in a 15% reduction in visceral fat," reports a meaningful reduction in visceral fat during therapy, which is important for reducing metabolic risk
The medication itself, compounded tirzepatide, contains the same active ingredient as brand-name Mounjaro and Zepbound
And taking Jardiance and Ozempic together could cause a double whammy of hypoglycemia, so its important to monitor your blood sugar when starting or increasing these drugs, Luren says
Review clinical trial data, warning signs, risk factors, and proven prevention strategies from physicians
The information presented here describes research findings and should not be construed as medical advice or claims about therapeutic benefits